Lucassin® (terlipressin)
« BACK
Hepatorenal syndrome, or HRS Type 1, is a rare and often fatal condition of advancing kidney failure in patients with cirrhosis or other severe liver diseases. In many of these patients, a successful liver transplant is their only hope to reverse HRS Type I and restore normal kidney function.
Unfortunately many patients with end-stage liver disease and HRS Type 1 may not survive long enough to receive a donor organ.
Terlipressin helps to increase the likelihood of HRS Type 1 reversal by redistributing blood flow to the kidneys. By jump-starting normal renal function, terlipressin allows patients to get past the immediate crisis of HRS Type 1.1-4
References
- Saner FH, Canbay A, Gerken G, Broelsch CE. Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome. Expert Rev Gastroenterol Hepatol. 2007;1(2):207-217.
- Döhler KD, Meyer M. Vasopressin analogues in the treatment of hepatorenal syndrome and gastrointestinal haemorrhage. Best Pract Res Clin Anaesthesiol. 2008;22(2):335-350.
- Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134(5):1360-1368.
- Fabrizi F, Dixit V, Martin P. Meta-analysis: terlipressin therapy for the hepatorenal syndrome. Aliment Pharmacol Ther. 2006;24(6):935-944.
